ArticleCancer management and research2025
Immunotherapy Rechallenge of Advanced NSCLC with Acquired EGFR T790M Mutation after EGFR-TKI Therapy: A Case Report.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance.Frontiers in immunology · 2026Review
- Cadonilimab rechallenge in patients with recurrent or metastatic cervical cancer following prior PD-1/PD-L1 inhibitor failure: a retrospective multicenter study.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma remains a leading cause of cancer mortality globally. While immune checkpoint inhibitors (ICIs) have improved outcomes in advanced non-small cell lung cancer (NSCLC), their efficacy in patients with acquired epidermal growth factor receptor (EGFR) T790M mutations following multiline therapy is poorly defined. This case report describes a 52-year-old Asian female never-smoker diagnosed with stage IIIA lung adenocarcinoma. She underwent lobectomy and received multiple lines of therapy. Initial genetic testing showed no EGFR T790M mutation, but subsequent testing after multiline treatment confirmed its acquired presence. Following multiline therapeutic failure, the patient received immunotherapy with cadonilimab (a PD-1/CTLA-4 bispecific antibody). This intervention resulted in disease control, and the patient achieved 9.4 months of progression free survival (PFS). This case suggests that immunotherapy with cadonilimab could be a potential consideration for advanced NSCLC harboring acquired EGFR T790M mutation post-multiline therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.